No

Toxoid

Detection of delayed hypersensitivity and assessment of cell-mediated immunity; active immunization against tetanus in the rare adult or child who is allergic to the aluminum adjuvant (a product containing adsorbed tetanus toxoid is preferred)

C

Hypersensitivity to tetanus toxoid or any product components

Epinephrine 1:1000 should be readily available; skin test responsiveness may be delayed or reduced in elderly patients

Percentage unknown: Very hypersensitive persons may develop a local reaction at the injection site; urticaria, anaphylactic reactions, shock and death are possible

Increased effect: Cimetidine may augment delayed hypersensitivity responses to skin test antigens

Refrigerate

Tetanus toxoid preparations contain the toxin produced by virulent tetanus bacilli (detoxified growth products of Clostridium tetani). The toxin has been modified by treatment with formaldehyde so that is has lost toxicity but still retains ability to act as antigen and produce active immunity.

Anergy testing: Intradermal: 0.1 mL

Primary immunization ( Note: Td, TD, DTaP/DTwP are recommended): Adults: Inject 3 doses of 0.5 mL I.M. or S.C. at 4- to 8-week intervals; administer fourth dose 6-12 months after third dose

Booster doses: I.M., S.C.: 0.5 mL every 10 years

Must not be used I.V.

No information available to require special precautions

No effects or complications reported

A nodule may be palpable at the injection site for a few weeks

Injection, fluid:

Tetanus 5 Lf units per 0.5 mL dose (0.5 mL, 7.5 mL)

Gardner P and Schaffner W, "Immunization of Adults," N Engl J Med, 1993, 328(17):1252-8.